Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4 acetylaminoisoindoline 1,3-dione
Stereomerically pure (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, substantially free of its (−) isomer, and prodrugs, metabolites, polymorphs, salts, solvates, hydrates, and clathrates thereof are discussed. Also discussed are methods of using and pharmaceutical compositions comprising the (+) enantiomer of 2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione are disclosed. The methods include methods of treating and/or preventing disorders ameliorated by the reduction of levels of TNF-α or the inhibition of PDE4.
1. A method of treating cancer, wherein the cancer is a solid tumor or a blood-born tumor, which comprises administering to a patient in need of such treatment a therapeutically effective amount of stereomerically pure (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, or a pharmaceutically acceptable salt, or solvate thereof.
2. The method of claim 1 further comprising administering to a patient in need of such treatment a therapeutically effective amount of an alkylating agent, nitrogen mustard, a JNK inhibitor, antibiotic, antineoplastic agent, exhylenimine, methyhuelamine alkyl sulfonate, nitrosourea, triazene, folic acid analog, pyrimidine analog, purine analog, vinca alkaloid, epipodophyllotoxin, a topoisornerase inhibitor, or an anti-cancer vaccine.
3. The method of claim 1 wherein the cancer is selected from the group consisting ox multiple myelorna, acute leukemia, chronic leukemia, lymphoblastic leukemia, myclogenous leukemia, lymphocytic leukemia, and myelocytic leukemia.
4. The method of claim 1 wherein the solid tumor is selected from the group consisting of a tumor of the breast, colon rectum, colorectum, kidney, and a glioma.
5. The method of claim 1 wherein the patient is a mammal.
6. The method of claim 1 wherein the stereomerically pure (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione is administered parenterally, transderrnally, mucosally, nasally, buccally, sublingually, or orally.
7. The method of claim 6 wherein the stereomerically pure (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl-]4-acetylaminoisoindoline-1,3-dione is administered orally.
8. The method of claim 7 wherein the stereomerically pure (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl-]4-acetylaminoisoindoline-1,3-dione is administered orally in a tablet or capsule form.
9. The method of claim 8 wherein the therapeutically effective amount is from about 1 mg to about 1000 mg per day.
10. The method of claim 9 wherein the therapeutically effective amount is from about 5 mg to about 500 mg per day.
11. The method of claim 10 wherein the therapeutically effective amount is from about 10 mg to about 200 mg per day.
12. The method of claim 3 wherein the lymnphocytic leukemia is chronic lymphocytic leukemia.
13. The method of claim 1 wherein the stereoflierically pure (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methysulfonylethyl]-4-acetylaminoisoindoline-1,3-dione is administered topically.
14. The method of claim 13 wherein the stereomerically pure (+)-2-[1-(-3-Ethoxy-4-methoxyphenyl)-2-methylsulfonyl]-4-acetylaminoisoindoline 1,3-dione is administered in a form of ophthalmic solution, spray, aerosol, cream, lotion, ointment, gel, solution, emulsion, or suspension.
15. The method of claim 14 wherein the therapeutically effective amount is from about 1 mg to about 1000 mg per day.
16. The method of claim 15 wherein the therapeutically effective amount is front about 5 mg to about 500 mg per day.
17. The method of claim 16 wherein the therapeutically effective amount is from about 10 mg to about 200 mg per day.